Pacemakers (Russian market)

Main article: Pacemakers

Pacemakers (Global Market)

Main Article: Pacemakers (Global Market)

Chronicle

Russian Apollo MRI electrocardiostimulator released, with which you can go to the MRI scanner

Rostec State Corporation has launched mass production of the first domestic electrocardiostimulator compatible with magnetic resonance imaging. The Apollo MRI device is designed for patients with severe arrhythmias. The main advantage of the device is the ability to undergo MRI examinations without restrictions, which is not available when using conventional models. The start of the issue was reported by the Rostec press service on October 6, 2025. Read more here

2024: Production growth of 18% to 7,783

The production of pacemakers in Russia in 2024 increased by 18% and amounted to 7,783 units, which was the result of an increase in demand for medical devices, the course for import substitution and state support for domestic manufacturers in the context of the development of related technological areas. The positive dynamics of the industry in 2024 contrasts with the volatility of previous years, when the output of pacemakers showed significant fluctuations from a maximum of 7,890 units in 2020 to a minimum of 5,330 units in 2021. This is evidenced by data from the BusinesStat study, published in August 2025.

The industry has shown uneven development dynamics over a five-year period, analysts said. The five largest Russian manufacturers of pacemakers include:

• LLC "Cardioelectronics"
• DMS Advanced Technologies LLC
• Elestim-Cardio LLC
• Lorge Medical LLC
• Cardix CJSC

𝓲

Фото: Freepik

The study notes that the industry faced serious difficulties in 2021, and the production of pacemakers decreased by 32.4% to 5,330 units. This decline was the most significant drop in the period analyzed and reflected systemic problems in the medical industry.

The recovery began in 2022, when production rose 42.8% to reach 7,610 units. Such a sharp increase partially compensated for the losses of the previous year and brought output volumes closer to the level of 2020.

In 2023, the industry again showed negative dynamics with a decrease of 13.2% to 6,610 units. The repeated reduction in production indicated continued instability in the medical device market.

The growth in the production of pacemakers in 2024 by 17.8% to 7,783 units is due to a complex of factors. The general increase in demand for pacemakers is associated with an increase in the number of cardiovascular diseases, post-covid syndrome and demographic aging of the Russian population.^[1]

2023: 8.5% reduction in sales to RUB 2.7 billion

In 2023, sales of pacemakers of imported and domestic production in Russia amounted to about 2.7 billion rubles. This is 8.5% less compared to the previous year, when the market volume was estimated at 3 billion rubles. Such data are given in the review of the analytical agency "GuideMarket," published on August 25, 2024.

The study says that the most popular on the Russian market are implantable two-chamber and three-chamber electrocardiostimulants (ECS), which can control and stimulate the work of two and three heart chambers, respectively. Single-chamber devices are used less often because they have limited functionality and are not able to ensure optimal heart function in patients with complex forms of arrhythmia.

According to estimates, in 2019, the total sales of pacemakers of imported and domestic production in the Russian Federation amounted to 2.07 billion rubles. In 2020, there was a decrease of 12.6% - to 1.81 billion rubles. The review notes that the Russian pacemaker market remains dependent on foreign supplies. Therefore, against the background of the COVID-19 pandemic, which provoked a disruption in the supply chains, there was a drop in sales.

In 2021, the industry began to recover, showing an increase of 11.4% with a final result of 2 billion rubles. In 2022, there was an increase in sales by another 48.1%, but in 2023 there was a decline. Due to the deteriorating geopolitical situation, there was a shortage of medical devices for patients with heart pathologies, the work of both state and commercial medical organizations became much more complicated. Problems with the import of equipment, consumables and components led to an increase in the cost of services of private clinics. On the other hand, the formed situation led to the accelerated development of import substitution of goods in the field of cardiology.^[2]

Notes